Features of liver damage in patients with thyrotoxicosis: clinical observation of hepatopathy against the background of taking thyreostatics

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Metabolic processes in the liver are closely related to the work of the thyroid gland. In this regard; it is necessary to exclude the pathology of the thyroid gland with an increase in the transaminase level for an unknown reason. It is known that diffuse toxic goiter is the leading cause of thyrotoxicosis. In patients with newly diagnosed hyperthyroidism; biochemical abnormalities in the blood test; indicating liver dysfunction; are recorded quite often; while clinical manifestations; as a rule; may not be expressed. The article discusses the issues of diagnosing hepatopathy in patients with thyrotoxicosis; the need to differentiate true thyrotoxic damage from concomitant liver diseases of a viral and autoimmune nature; drug-induced liver damage. The authors present a clinical case of acute toxic hepatitis caused by thiamazole in a patient with diffuse toxic goiter.

Full Text

Restricted Access

About the authors

Svetlana V. Bulgakova

Samara State Medical University

Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0003-0027-1786
Russian Federation, Samara

Lyudmila A. Sharonova

Samara State Medical University

Author for correspondence.
Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0001-8827-4919

Cand. Sci. (Med.), Associate Professor; Department of Endocrinology and Geriatrics

Russian Federation, Samara

Yuliya A. Dolgikh

Samara State Medical University

Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0001-6678-6411
Russian Federation, Samara

Olga V. Kosareva

Samara State Medical University

Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0002-5754-1057
Russian Federation, Samara

Ekaterina V. Treneva

Samara State Medical University

Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0003-0097-7252
Russian Federation, Samara

Dmitry P. Kurmaev

Samara State Medical University

Email: l.a.sharonova@samsmu.ru
ORCID iD: 0000-0003-4114-5233
Russian Federation, Samara

References

  1. Буеверов А.О.; Богомолов П.О.; Нечаева О.А.; Зилов А.В. Причинно-следственная связь патологии щитовидной железы и печени. Медицинский совет. 2021;(15):88–94. [Bueverov A.O.; Bogomolov P.O.; Nechayeva O.A.; Zilov A.V. Cause-and-effect relationship between thyroid and liver diseases. Meditsinskiy sovet=Medical Council. 2021;(15):88–94. (In Russ.)]. doi: 10.21518/2079-701X-202115-88-94.
  2. Якубовская А.Г.; Колдынская Э.И. Случай латентного течения тиреотоксикоза с преимущественно печеночными проявлениями. Экспериментальная и клиническая гастроэнтерология. 2022;206(10): 175–79. [Iakubovs-kaia A.G.; Koldynskaia E.I. A case of latent course of thyrotoxicosis with predominantly hepatic manifestations. Eksperimental’naya i klinicheskaya gastroenterologiya. 2022;206(10):175–79. (In Russ.)]. doi: 10.31146/1682-8658-ecg-206-10-175-179.
  3. Артыкбаева Г.М. Роль дейодиназ 1-го и 2-го типов в метаболизме тиреоидных гормонов (обзор литературы). Проблемы эндокринологии. 2016;62(2):46–51. [Artykbaeva GM. Role of type 1 and 2 deiodinases in thyroid metabolism (review). Problemy Endokrinologii. 2016;62(2):46–51. (In Russ.)]. doi: 10.14341/probl201662246-52.
  4. Smith T.J.; Hegedus L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65. doi: 10.1056/NEJMra1510030.
  5. Taylor P.N.; Albrecht D.; Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301–16. doi: 10.1038/nrendo.2018.18.
  6. Kahaly G.J.; Bartalena L.; Hegedus L.; et al. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86. doi: 10.1159/000490384.
  7. Ippolito; S.; Cusini; C.; Lasalvia; P. et al. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021;44:1707–18. doi: 10.1007/s40618-020-01479-z.
  8. Piantanida E.; Ippolito S.; Gallo D. et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest. 2020;43(7):885–99. doi: 10.1007/s40618-020-01208-6.
  9. Eshraghian A.; Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25): 8102–109. doi: 10.3748/wjg.v20.i25.8102.
  10. Kishore K.; Adhya A.K. Graves’ disease with Pancytopenia and Hepatic Dysfunction: A Rare Case Presentation. Ind J Nuclear Med.2019;34:38–41.
  11. Halawi A.; Bitar R.; Ibrahim N. Hyperthyroidism as a Potential Trigger for Benign Recurrent Intrahepatic Cholestasis. ACG Case Rep J. 2020;7(7):e00423. doi: 10.14309/crj.0000000000000423.
  12. Guo W.; Qin P.; Li X.N.; et al. Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2021;12:711956. doi: 10.3389/fendo.2021.711956.
  13. Lian H.; Yang H.B.; Guo X.X.; et al. Severe Hyperthyroidism-Heart Failure-Severe Liver Injury: Report of One Case and Literature Review. Acta Acad Med Sin. 2019;41(1):134–38. Chinese. doi: 10.3881/j.issn.1000-503X.10722.
  14. Пикулев Д.В.; Клеменов А.В. Тиреотоксический гепатит. Проблемы эндокринологии. 2017;63(1):46–50. [Pikulev DV; Klemenov AV. Thyrotoxic hepatitis. Problemy endokrinologii. 2017;63(1):46–50. (In Russ.)]. doi: 10.14341/probl201763146-50.
  15. Zeng B.; Yuan L.; Chu J.; et al. Challenges in early identification of causes and treatment of cholestasis in patients with hyperthyroidism: a case report and literature review. J Int Med Res. 2019;48(3):300060519891018. doi: 10.1177/0300060519891018.
  16. Burra P. Liver abnormalities and endocrine diseases. Best Pract Res Clin Gastroenterol. 2013;27(4):553–63. doi: 10.1016/j.bpg.2013.06.014.
  17. Hsieh A.; Adelstein S.; Twigg S.M. Liver enzyme profile and progression in association with thyroid autoimmunity in Graves’ disease. Endocrinol Diabetes Metab.2019:2(4):1–7. doi: 10.1002/edm2.86.
  18. Shen Q.; Wang Q.; Zang H.; et al. DRESS/DiHS syndrome induced by Propylthiouracil: a case report. BMC Endocr Disord. 202;23(1):22. doi: 10.1186/s12902-023-01273-x.
  19. Zeng J.; Luo F.; Lin Z.; et al. Rash and cholestatic liver injury caused by methimazole in a woman with Turner syndrome and Graves’s disease: a case report and literature review. BMC Endocr Disord. 2021;21(1):179. doi: 10.1186/s12902-021-00819-1.
  20. Heidari R.; Niknahad H.; Jamshidzadeh A.; et al. An Overview on the Proposed Mechanisms of Antithyroid DrugsInduced Liver Injury. Adv Pharm Bull. 2015;5(1):1–11. doi: 10.5681/apb.2015.001.
  21. Пиманов С.И.; & Макаренко Е.В. Идио-синкразические лекарственные поражения печени: диагностика и лечение. Медицинский совет. 2017;5:100–7. [Pimanov S.I.; Makarenko E.V. Idiosyncratic drug-induced liver injury: diagnosis and treatment. Meditsinskiy sovet=Medical Council. 2017;(5):100–7. (In Russ.)]. doi: 10.21518/2079-701X-2017-5-100-107.
  22. Валеева Ф.В.; Красильников Д.М.; Бареева Л.Т.; Шакуло А.В. Осложнения тиреостатической терапии при болезни Грейвса. Практическая медицина. 2021;19(6):6–9. [Valeeva F.V.; Krasil’nikov D.M.; Bareeva L.T.; Shakulo A.V. Complications of thyrostatic treatment of Graves disease. Practiccheskaya meditsina. 2021;19(6):6–9. (In Russ.)]. doi: 10.32000/2072-1757-2021-6-6-9.
  23. Хлынова О.В.; Гирфанова Л.Г. Клинический случай тиреотоксического гепатита. Доказательная гастроэнтерология. 2020;9(3):73–6. [Khlynova O.V.; Girfanova L.G. Clinical case of thyrotoxic hepatitis. Dokazatel’naya gastroenterologiya=Russian Journal of Evidence-Based Gastroenterology. 2020;9(3):73–6. (In Russ.)]. doi: 10.17116/dokgastro2020903173.
  24. Trusau A.; Brit M.L. Propylthiouracil-induced ANCA-negative cutaneous small vessel vasculitis. J Community Hosp Intern Med Perspect. 2018;8(1):35–7. doi: 10.1080/20009666.2017.1422673.
  25. Eser M.; Basyigit S.; Eser M.; Nazligul Y. Propylthiouracil-related Toxic Hepatitis: Impact of Silent Cases. Euroasian J Hepatogastroenterol. 2015;5(2):134–35. doi: 10.5005/jp-journals-10018-1153.
  26. Li X.; Jin S.; Fan Y.; Fan X.; et al. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves’ disease patients. Biomed Pharmacother. 2019;117:109095. doi: 10.1016/j.biopha.2019.109095.
  27. Khaled Ahmed Baagar; Mashhood Ahmed Siddique; Shaimaa Ahmed Arroub; et al. «Atypical Complications of Graves’ Disease: A Case Report and Literature Review»; Case Reports in Endocrinology; 2017;2017:6087135. doi: 10.1155/2017/6087135.
  28. Курченкова; В.И. Капралов; Н.В.; Шоломиц-кая И.А. Аутоиммунные заболевания печени: клиническое течение и современная терапия. Медицинский журнал. 2019;4(70):21–7. [Kurchenkova; V.I. Kapralov; N.V.; Sholomickaya I.A. Autoimmune liver diseases: clinical course and modern therapy. Meditsinskii zhurnal=Medical Journal. 2019;4(70):21–7. (In Russ.)].
  29. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol.2015;63(4):971–1004. doi: 10.1016/j.jhep.2015.06.030.
  30. Teufel A.; Weinmann A.; Kahaly G. J.; et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44(3):208–13. doi: 10.1097/MCG.0b013e3181c74e0d.
  31. Muratori P.; Fabbri A.; Lalanne C.; et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur. J. Gastroenterol. Hepatol. 2015;27(10):1175–79. doi: 10.1097/MEG.0000000000000424.
  32. Цыркунов В.М.; Прокопчик Н.И.; Андреев В.П. Аутоиммунный гепатит: морфологические аспекты. Гепатология и гастроэнтерология. 2021;5(1):5–16. [Tsyrkunov V.M.; Prokopchik N.I.; Andreev V.P. Autoimmune hepatitis: morpholo-gical aspects. Hepatology and Gastroentero-logy. 2021;5(1):5–16. (In Russ.)]. doi: 10.25298/2616-5546-2021-5-1-5-16.
  33. Ливзан М.А.; Гаус О.В.; Гавриленко Д.А. Манифестный гипертиреоз у пациентки с аутоиммунным гепатитом (клиническое наблюдение). Медицинский алфавит. 2021; (35):52–6. [Livzan M.A.; Gaus O.V.; Gavrilenko D.A. Manifest hyperthyroidism in patient with autoimmune hepatitis (clinical observation). Medical alphabet. 2021;(35):52–6. (In Russ.)]. doi: 10.33667/2078-5631-2021-35-52-56.
  34. Floreani A.; Restrepo-Jimenez P.; Secchi M.F.; et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133–43. doi: 10.1016/j.jaut.2018.10.020.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies